Skip to main content

Table 1 sGC ligands inhibit cardiomyocyte hypertrophy

From: Antihypertrophic actions of NO-independent soluble guanylyl cyclase (sGC) ligands BAY 41-2272 and BAY 58-2667 in vitro

 

Control

ET1 alone

ET1 + BAY (0.01 μM)

ET1 + BAY (0.03 μM)

ET1 + BAY (0.10 μM)

ET1 + BAY (0.30 μM)

Cell size (% paired control cardiomyocytes, both n = 4)

BAY 41-2272

100 ± 0%

146 ± 9%*

128 ± 5%#

116 ± 7%#

106 ± 6%#

108 ± 6%#

BAY 58-2667

100 ± 0%

141 ± 8%*

133 ± 11%

123 ± 7%#

113 ± 2%#

108 ± 12%

De novo protein synthesis (% paired control cardiomyocytes, n = 5–6)

BAY 41-2272

100 ± 0%

122 ± 1%*

102 ± 1%#

101 ± 1%#

102 ± 2%#

110 ± 0%#

BAY 58-2667

100 ± 0%

135 ± 2%*

110 ± 3%

117 ± 3%

107 ± 2%#

108 ± 3%

  1. *p < 0.05 versus control; #p < 0.05 versus ET1, on one-way RM. DMSO, the vehicle for the sGC ligands, had no effect on either parameter either alone, or in the presence of ET1.